Company
Every investor coverage indicates participated in a round Buchan Consulting raised.
Companies Buchan Consulting acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Haley Price | GBS Ventures (Thu 12 Dec 2013), GBS Ventures (Thu 31 Oct 2013) | |
| Kyahn Williamson | Investor and Media Relations (former) | GBS Ventures (Wed 2 Sep 2015), GBS Ventures (Mon 31 Aug 2015) |
Stories naming Buchan Consulting. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Breast reconstruction device maker AirXpanders has lodged a 510(k) regulatory submission with US authorities for its needle-free AeroForm tissue expander, following positive clinical trial results, as it moves toward entering the American market.
ASX-listed breast reconstruction device maker AirXpanders reports its pivotal XPAND trial met its primary endpoint, with results to go to the US regulator and be presented at a plastic surgery meeting in Boston.
Hatchtech announced FDA sign-off on its DeOvo Phase 3 trials and two extra patents; its profile names GBS Venture Partners among the company's investors.
Melbourne drug developer Hatchtech raised A$12.6 million, with OneVentures Innovation Fund leading, to advance its head lice treatment toward Phase III trials; board changes brought in Richard Treagus and Hugh Alsop.